A new Frontiers in Aging review identifies a coming third wave of therapeutic peptides targeting the root mechanisms of aging � cellular senescence, mitochondrial dysfunction, telomere biology, and cognitive decline � moving well beyond weight loss and GH optimization.
A sweeping review published in Frontiers in Aging (2026) has mapped what researchers are calling the third wave of peptide therapeutics in gerontology. The first wave brought GH secretagogues and healing peptides; the second wave introduced GLP-1 receptor agonists revolutionizing metabolic medicine. Now a new class of compounds is emerging that targets fundamental aging hallmarks: cellular senescence clearance, mitochondrial dysfunction, telomere attrition, and neurological decline.
Among the most closely watched compounds are SS-31 (Elamipretide), a mitochondria-targeted tetrapeptide that stabilizes cardiolipin and restores electron transport chain efficiency � currently in clinical trials for heart failure and mitochondrial disease. FOXO4-DRI, a senolytic peptide that selectively induces apoptosis in senescent "zombie" cells, is gaining research interest for its potential to reduce the chronic inflammation (inflammaging) that drives multiple age-related conditions simultaneously.
On the cognitive front, peptides such as Dihexa, an angiotensin IV analog, and the nootropic peptides Semax and Selank developed in Russia are attracting renewed scientific attention. MOTS-c, a mitochondria-derived peptide, has shown in multiple 2026 studies that it improves metabolic flexibility and insulin sensitivity while acting as an exercise mimetic � potentially addressing the metabolic decline that accelerates aging in sedentary populations.
The review authors note a critical regulatory challenge: most of these third-wave peptides lack the large-scale human trial data needed for FDA approval, creating a landscape where compelling preclinical evidence exists but clinical translation has been slow. As longevity medicine grows into a recognized specialty, calls are intensifying for regulatory pathways that recognize healthspan extension as a valid clinical endpoint � a shift that would unlock investment in the trials these compounds urgently need.
Source: Frontiers in Aging
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.